




The relative strengths and weaknesses of Sciclone Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sciclone Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Sciclone Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 390%, being 127% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	168,521
Cost of Goods Sold	0
Intangible Assets	32,979
Liabilities, Current	36,820
Liabilities, Non-Current	0
Other Assets	12,468
Other Compr. Net Income	-1,194
Other Expenses	100,256
Other Liabilities	0
Other Net Income	359
Other Revenues	157,257
Property and Equipment	2,651
Research and Development	0
Selling, General and Administrative Expense	27,897

Output Variable	Value in 1000 USD
Assets	216,619
Liabilities	36,820
Expenses	128,153
Revenues	157,257
Stockholders Equity	179,799
Net Income	29,463
Comprehensive Net Income	28,866
BaseVar	270,201
ECR before Limited Liability	332%
Economic Capital Ratio	390%